Lilly reports lower sales in drugs with higher rebates

Lilly's first quarter revenues fell short of expectations, driven by lower-than-expected sales from drugs affected by high rebate rates. The pharma said it believes proposed rebate reforms could have a positive impact on future volume, and isn't

Read the full 371 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE